Anthony A. Rascio, J.D. Anthony Rascio, J.D., was Senior Vice President and Corporate Secretary of Esprit Pharma, a pharmaceutical company focused on the genitourinary (GU) and women s healthcare markets. Esprit Pharma marketed SANCTURA (trospium chloride) for the treatment of overactive bladder (OAB), and ESTRASORB (estradiol topical emulsion) for vaso-motor symptoms associated with menopause. Mr. Rascio was instrumental in Esprit Pharma successfully completing a Series B funding round, raising $90 million in financing from a group of leading venture capital and private equity investors. Firms participating in the Series B round included New Enterprise Associates, Apax Partners, Domain Associates, Montagu Newhall Global Partners, and Oak Investment Partners. Allergan (NYSE: AGN) acquired Esprit Pharma in a $370 million all-cash transaction in 2007. Prior, Mr. Rascio served as Senior Vice President and General Counsel for ESP Pharma where he was responsible for acquisitions, licensing, financing, patent, trademark, and copyright matters. Before that, he was Vice President and General Counsel of Roberts Pharmaceutical Corporation where he counseled the company in raising capital in excess of $400 million, negotiated multi-million dollar licensing arrangements with US, European, and Japanese companies, and led the merger with Shire Pharmaceuticals of London. Earlier in his career, Mr. Rascio served as Legal Director, International Division, for Schering-Plough where he advised senior management on corporate and inter-divisional matters and managed a staff of attorneys, para-professionals, and clerical personnel. Mr. Rascio received his undergraduate and J.D. degrees from Fordham University.